Fabrication of mesoporous silica nanoparticles for targeted delivery of sunitinih to ovarian cancer cells

• Published in: Bioimpacts 2023-01, Vol.13 (3), p.255-267
• Main Authors: Torabi, Mitra, Aghanejad, Ayuob, Savadi, Pouria, Barzegari, Abolfazl, Omidi, Yadollah, Barar, Jaleh
• Format: Article
• Language: English
• Subjects: Acetic acid; Ammonium nitrate; Angiogenesis; Angiogenesis inhibitors; Antibodies; Biocompatibility; Biomarkers; Cell cycle; Chemotherapy; Clinical trials; Dichloromethane; Dimethyl sulfoxide; Drug delivery; Drug delivery systems; Drug resistance; Ethanol; Ethyl acetate; Metastases; Metastasis; Nanoparticles; Ovarian cancer; Permeability; Polyethylene glycol; Pore size; Sodium hydroxide; Tetraethoxysilane; Tomography; Tumors; Vascular endothelial growth factor; Womens health
• ISSN: 2228-5652; 2228-5660
• DOI: 10.34172/bi.2023.25298

The cell cycle analysis exhibited that the induction of sub-Gl phase arrest mostly occurred in MSNP-PEG/ SUN-MUC16 treated OVCAR-3 cells and MSNP-PEG/SUN treated SK-OV-3 cells. Studies have shown that receptor tyrosine kinases (RTKs) are considered critical markers for tumor progression and resistance to chemotherapy since their complicity has been revealed in about one-third of metastatic ovarian cancer.6 Surprisingly recurrent drug resistant forms of ovarian cancer exhibit more sensitivity to the kinase inhibitors than platinum-based treatment regimens.7 Sunitinib malate, a novel multi-targeted RTK inhibitor, has demonstrated moderate effectiveness in several phase II clinical trials for ovarian cancer, showing a potential treatment regimen for the resistant recurrence of tumor in the future.8,9 Furthermore, angiogenesis as a common phenomenon in ovarian cancer could also be efficiently inhibited by SUN. SUN is one of the foremost selective angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF); hence, it has received immense attention to combat ovarian cancer.1012 Nowadays, the development of seamless drug delivery systems (DDSs) armed with imaging and targeting agents for simultaneous diagnosis and treatment of cancer has presented a greater significance because of the selectivity and specificity of their effect.13 Pertinently, mesoporous silica nanoparticles (MSNPs) regarding their unique characteristics such as large surface area (700-1000 m2 g_1) with high drug loading efficiency, tailor-made pore size (0.6-1 cm3 g_1), outstanding biodistribution, and biocompatibility are considered as promising nanosystems (NSs) for imaging and treatment applications.14 MSNPs depending on their capabilities can accumulate in the tumor micro environment (TME) up to 70-fold. Materials and Methods Materials Cetyl trimethylammonium bromide (CTAB), tetraethyl orthosilicate (TEOS), sodium hydroxide (NaOH), ethyl acetate, ammonium nitrate, dichloromethane, acetone, diethyl ether, dimethyl sulfoxide (DMSO), sodium borohydride, 3-(triethoxysilyl)propylamine were obtained from Merck (Darmstadt, Germany).